saldisk 50 µg/1 doza+ 100 µg/1 doza prašak inhalata, dozirani
salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 100 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 100 µg flutikazonpropionata
saldisk 50 µg/1 doza+ 250 µg/1 doza prašak inhalata, dozirani
salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 250 µg/1 doza - 1 doza praška inhalata doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 250 µg flutikazonpropionata
saldisk 50 µg/1 doza+ 500 µg/1 doza prašak inhalata, dozirani
salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 500 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 500 µg flutikazonpropionata
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastična sredstva - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
sycrest
n.v. organon - asenapine (as maleate) - bipolarni poremećaj - psycholeptics - sycrest je indiciran za liječenje umjerenih do teških maničnih epizoda povezanih s bipolarnim poremećajem u odraslih osoba.
benlysta
glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemski - imunosupresivi - benlysta navodi kao dopuna terapije kod pacijenata u dobi od 5 i više godina uz aktivnu, pozitivnu аутоантитела sistemski eritemski lupus (sle) s visokim stupnjem aktivnosti bolesti (e. pozitivna anti-ova dnk i niska razina komplementa), bez obzira na standardnu terapiju. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
cetrotide
merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - hipofiza i hipotalamusni hormoni i analozi - prevencija preuranjene ovulacije kod pacijenata koji su podvrgnuti kontroliranoj stimulaciji jajnika, nakon čega slijedi uzimanje oocita i pomoćno-reproduktivne tehnike. u kliničkim ispitivanjima, cetrotide koristi ljudski менопаузальный gonadotropin (hmg), međutim, ograničeno iskustvo primjenu rekombinantnog folikul stimulirajući (fsh) ponudili istu učinkovitost.